SCHEMBL2209486

SCHEMBL2209486

N#Cc1ccc2c(Oc3ccc(Nc4nnc(-c5ccccc5)c5ccccc45)cc3)ccnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 2/20 0.48
AURKA O14965 1/20 0.47
AURKB Q96GD4 1/20 0.47
TPX2 Q9ULW0 1/20 0.47
MAPT P10636 7/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
ENPP3 O14638 3/20 0.42
TP53 P04637 2/20 0.42
GAA P10253 2/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
IKBKB O14920 1/20 0.42
KDR P35968 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PDE5A O76074 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213005 0.96 IKBKB (0.46) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2208492 0.93 KDR (0.46) FGFR2MAPTLMNAPOLBENPP3
SCHEMBL2211970 0.93 AURKA (0.48) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2208494 0.93 MAPT (0.54) FGFR2MAPTLMNAPOLBENPP3
SCHEMBL2211183 0.93 FGFR2 (0.48) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2211314 0.91 MAPT (0.43) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2211365 0.91 KDR (0.44) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL3737329 0.88 ALDH1A1 (0.39) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2207468 0.88 FGFR2 (0.41) FGFR2MAPTLMNAPOLBENPP3
SCHEMBL2209401 0.87 AURKA (0.46) FGFR2AURKAAURKBTPX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 FGFR2 334/4885AURKA 2/4885AURKB 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.